Oncology News
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?


Article ID

Home
General Oncology
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain Management/
    Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
Top Ten Searches
brca1  brca1
prostate-specific antigen  prostate-specific antigen
sclc  sclc
fobt  fobt
egd  egd
bmi  bmi
dysplasia  dysplasia
hematologic  hematologic
ovarian  ovarian
hcc  hcc
 
Sponsor
MDLinx Email Article

To email this article, enter your own "From Email" address,
the recipient's "To Email" address, and click the "Send Email" button.
You may send to up to 5 email addresses.
*From Email:  
*To Email:  
To Email:  
To Email:  
To Email:  
To Email:  
Radiation therapy in addition to gross total resection of retroperitoneal sarcoma results in prolonged survival: results from a single institutional study
Zagar TM et al. - In a study to assess the survival advantage of radiation therapy (RT) in addition to gross total resection of retroperitoneal sarcoma (RPS), it was concluded that compared with surgery alone, neoadjuvant or adjuvant RT offers these pts an excellent chance for long-term locoregional control (LRC), distant disease free survival (DDFS), and overall survival (OS). The integration of modern treatment planning for external beam radiation therapy and intraoperative radiation therapy (IORT) allows for higher doses to be delivered with acceptable toxicities.

Methods
  • 31 pts with RPS treated with gross total resection and RT make up this retrospective analysis.
  • 19 were treated preoperatively and 12 postoperatively (median dose, 59.4 Gy); 16 also received IORT (median dose, 11 Gy).
  • Pts were followed with stringent regimens, including frequent CT scans of the chest, abdomen, and pelvis.

Results
  • With a median follow-up of 19 mos, 2-yr OS rate is 70%.
  • 2-yr locoregional control (LRC) rate is 77%.
  • 2-yr DDFS rate is 70%.
  • There were no differences in radiation-related acute and late toxicities among pts treated pre- versus postoperatively, whether with or without IORT.
[more...]
Sponsor

Read a Different Specialty

Oncology Articles
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Profession Index

Oncology Articles
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2009 MDLinx, Inc.